Wang Chenyang, Kishan Amar U, Yu James B, Raldow Ann, King Christopher R, Iwamoto Keisuke S, Chu Fang-I, Steinberg Michael L, Kupelian Patrick A
Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
Department of Therapeutic Radiology, Yale New Haven Hospital, New Haven, Connecticut.
Adv Radiat Oncol. 2019 May 15;4(4):738-747. doi: 10.1016/j.adro.2019.05.003. eCollection 2019 Oct-Dec.
Second malignancies (SMs) after radiation therapy are rare but serious sequelae of treatment. This study investigates whether radiation therapy use is associated with changes in baseline SM risk.
We extracted all patients with cancer, with or without SM, in the Surveillance, Epidemiology, and End Results database from 1973 to 2014. Cumulative incidence of SM for patients stratified by radiation therapy status was calculated using a competing risk model, both for the entire cohort and for subgroups based on the primary tumor's anatomic location.
We identified 2,872,063 patients with cancer, including 761,289 patients who received radiation therapy and 2,110,774 who did not. The SM rate at 20 years for patients receiving radiation therapy versus no radiation therapy was 21.4% versus 18.8%. The relative risk for SM associated with radiation therapy for the overall group was 1.138 at 20 years. The relative risks for SM associated with radiation therapy to malignancies arising from central nervous system and orbits, head and neck, thorax, abdomen, and pelvis at 20 years were 0.704, 1.011, 0.559, 0.646, and 1.106 for men and 0.792, 1.298, 1.265, 0.780, and 0.988 for women, respectively.
The association between SM and radiation therapy varies with both sex and disease anatomic location, with the largest increase in SM seen in females irradiated to the head and neck region. Overall, the absolute change in SM rates associated with radiation therapy remains small, with differences in various clinical contexts.
放射治疗后的第二原发恶性肿瘤(SMs)虽罕见,但却是治疗的严重后遗症。本研究调查放射治疗的使用是否与基线SM风险的变化相关。
我们从1973年至2014年的监测、流行病学和最终结果数据库中提取了所有癌症患者,无论有无SM。使用竞争风险模型计算按放射治疗状态分层的患者的SM累积发病率,包括整个队列以及基于原发肿瘤解剖位置的亚组。
我们识别出2,872,063例癌症患者,其中761,289例接受了放射治疗,2,110,774例未接受放射治疗。接受放射治疗与未接受放射治疗的患者20年时的SM发生率分别为21.4%和18.8%。整个组中与放射治疗相关的20年时SM的相对风险为1.138。男性中,20年时与放射治疗相关的中枢神经系统和眼眶、头颈部、胸部、腹部及骨盆恶性肿瘤的SM相对风险分别为0.704、1.011、0.559、0.646和1.106,女性分别为0.792、1.298、1.265、0.780和0.988。
SM与放射治疗之间的关联因性别和疾病解剖位置而异,头颈部接受照射的女性中SM增加最多。总体而言,与放射治疗相关的SM发生率的绝对变化仍然较小,不同临床背景下存在差异。